I am a medical oncologist who specializes in the treatment of primary brain tumors. My laboratory studies signal transduction abnormalities in glioblastoma which might be targeted with new cancer therapeutics.
- Clinical Expertise: Primary Brain Tumors
- Languages Spoken: English
- Education: MD, Technical University Munich (Germany)
- Residencies: University of California, Los Angeles, Health Sciences Center
- Fellowships: University of California, Los Angeles, Health Sciences Center
- Board Certifications: Internal Medicine; Medical Oncology; Hematology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Ingo K. Mellinghoff
- A Phase I Study of AG-881 to Treat Advanced Solid Tumors, including Gliomas, that Contain Mutated IDH1 or IDH2
- A Phase I Study of Oral AG-120 in Patients with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation
- A Phase I/II Study of AG-221 in Patients with Advanced Solid Tumors (including Glioma) or Angioimmunoblastic T-Cell Lymphoma that Have an IDH2 Mutation
Clinical Trials Co-Investigated by Ingo K. Mellinghoff
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more